Skip to main content

Table 8 Overall survival and progression-free survival of patients with tumors of differing diameters

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Tumor diameter OS (months) P PFS (months) P
Median 95% CI Median 95% CI
Group 1
  < 5 cm 44 21.624–66.376 0.004 8 5.633–10.367 0.268
  ≥ 5 cm 17 11.806–22.194 7 4.915–9.085
Group 2
  < 7 cm 38 20.228–55.772 0.002 9 6.003–11.997 0.012
  ≥ 7 cm 14 10.409–17.591 5 3.007–6.993
  1. CI confidence interval, OS overall survival, PFS progressive free survival
\